TipRanksStock Market NewsAnalyst Explains Why They Downgraded Their Rating on Addex Therapeutics (ADXN)

Analyst Explains Why They Downgraded Their Rating on Addex Therapeutics (ADXN)

H.C. Wainwright analyst Ram Selvaraju downgraded Addex Therapeutics (ADXNResearch Report) to Hold today. The company’s shares closed last Wednesday at $1.11, close to its 52-week low of $1.05.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -43.4% and a 11.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Timber Pharmaceuticals, and Oramed Pharmaceuticals.

Addex Therapeutics has an analyst consensus of Hold.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $10.90 and a one-year low of $1.05. Currently, Addex Therapeutics has an average volume of 23.03K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company’s geographical area of operations includes Switzerland and Europe.

Read More on ADXN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More